Briana Contreras

A recent JAMA Pediatrics study revealed the enduring effectiveness of the HPV vaccine, highlighting its role in reducing cancer risk among young women.

AI revolutionizes member health risk identification, outperforming traditional models by integrating diverse data for proactive care in managed care settings.

New data reveals a rising trend in generalized anxiety disorder (GAD) prevalence among U.S. adults, emphasizing the need for improved diagnosis and treatment.

A study at AMCP Nexus 2025 reveals how drug rebates and net prices influence insurance coverage for specialty drugs, impacting patient access.

Shawn Kwatra, M.D., reveals new OX40 ligand therapies for atopic dermatitis, promising new hope for patients at the Fall Clinical Dermatology meeting.

Shawn Kwatra addresses the complexities of atopic dermatitis and prurigo nodularis at the Fall Clinical Dermatology Conference, emphasizing tailored treatment strategies.

Employer health premiums rose significantly this year, impacting healthcare costs and insurance access. A KFF survey reveals trends in coverage and employee contributions.

New findings reveal aflibercept 8 mg enhances vision and extends injection intervals for nAMD and DME patients, reducing treatment burden significantly.

Experts reveal strategies to improve breast cancer screening and outcomes for underserved communities, addressing disparities during Breast Cancer Awareness Month.

New research reveals AREDS vitamins do not slow geographic atrophy progression in AMD, urging patients to explore FDA-approved treatments instead.

Alfredo A. Sadun, M.D., Ph.D., discusses two applications of AI in ophthalmology where AI far exceeds what a human ophthalmologist can do.

Medical specialities, such as ophthalmology, that rely on imaging are among the early and most successful adoptors of artificial intelligenc

Biosimilars enhance arthritis treatment access, with rising adoption among women and long-term patients, revealing key prescribing patterns in Turkey.

New findings reveal significant geographic disparities in Medicare access, costs and quality, impacting millions of beneficiaries across the U.S.

Ruxolitinib cream shows promising results in repigmenting vitiligo lesions, enhancing skin appearance and quality of life with a strong safety profile.

Research reveals that even with over 25 million losing Medicaid during unwinding in 2023, the uninsured rate remains stable as many quickly re-enroll or switch coverage.

A study revealed that the 2024-2025 COVID-19 vaccine significantly reduces emergency visits, hospitalizations and deaths among U.S. veterans.

Experts discuss the implications of Most Favored Nation pricing on U.S. drug costs, innovation and patient access in the latest MJH Life Sciences webinar.

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved outcomes post-surgery and radiation.

The CDC updates vaccine schedules, emphasizing personalized decision-making for COVID-19 shots and recommending standalone chickenpox vaccines for toddlers.

Medicare beneficiaries face confusion during the Annual Enrollment Period, with significant plan changes ahead for 2026. Understanding options is crucial.

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, steroid-free solution.

A new study confirms ICD-10 code L80's high accuracy in identifying vitiligo, especially when combined with treatment data, enhancing clinical research.

Humana announces its 2026 Medicare Advantage and prescription drug plans, focusing on stable benefits, preventive care and enhanced member support.

UnitedHealthcare reveals its 2026 Medicare Advantage plans, featuring $0 premiums, expanded benefits and enhanced access to affordable healthcare options.

In this conversation with Kristin Begley, chief commercial officer at Capital Rx, we discussed the company’s recent rebrand to Judi Health and how it reflects broader trends in technology-driven, transparent PBMs.

Changes in eye blood vessels signal early risk for Alzheimer’s disease, offering a noninvasive biomarker for early detection and intervention.

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing patient access and competition.

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy changes effectively.

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing uncompensated care costs.